$58.78
0.89% day before yesterday
Nasdaq, May 30, 07:47 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$58.72
-12.10 17.09% 1M
+0.85 1.47% 6M
+3.44 6.22% YTD
-4.74 7.47% 1Y
+27.72 89.42% 3Y
+27.39 87.42% 5Y
+9.04 18.20% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.46 0.79%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Market capitalization $1.27b
Enterprise Value $1.74b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 26.12
EV/Sales (TTM) EV/Sales 2.14
P/S ratio (TTM) P/S ratio 1.57
P/B ratio (TTM) P/B ratio 2.87
Revenue growth (TTM) Revenue growth 56.85%
Revenue (TTM) Revenue $811.50m
EBIT (operating result TTM) EBIT $29.03m
Free Cash Flow (TTM) Free Cash Flow $66.61m
Cash position $155.19m
EPS (TTM) EPS $-0.32
P/E forward 38.19
P/S forward 1.62
EV/Sales forward 2.21
Short interest 10.81%
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
13%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
812 812
57% 57%
100%
- Direct Costs 323 323
68% 68%
40%
488 488
50% 50%
60%
- Selling and Administrative Expenses 326 326
88% 88%
40%
- Research and Development Expense 55 55
42% 42%
7%
120 120
7% 7%
15%
- Depreciation and Amortization 91 91
52% 52%
11%
EBIT (Operating Income) EBIT 29 29
44% 44%
4%
Net Profit -6.44 -6.44
121% 121%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:
Neutral
GlobeNewsWire
10 days ago
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of  acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the C...
Neutral
GlobeNewsWire
20 days ago
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today